UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 175

Sortiert nach

Invulnerability and the intention to drink and drive: An application of the theory of planned behavior

Accident analysis and prevention, 2010-11, Vol.42 (6), p.1549-1555

2010

Volltextzugriff (PDF)

The Severe Acute Respiratory Syndrome Coronavirus 3a Protein Up-Regulates Expression of Fibrinogen in Lung Epithelial Cells

Journal of Virology, 2005-08, Vol.79 (15), p.10083-10087

2005

Volltextzugriff (PDF)

Thermo‐Mechanically Stable, Liquid Metal Embedded Soft Materials for High‐Temperature Applications

Advanced functional materials, 2024-08, Vol.34 (31), p.n/a

2024

Volltextzugriff (PDF)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

BMC rheumatology, 2024-05, Vol.8 (1), p.20-20, Article 20

2024

Volltextzugriff (PDF)

The human severe acute respiratory syndrome coronavirus (SARS-CoV) 8b protein is distinct from its counterpart in animal SARS-CoV and down-regulates the expression of the envelope protein in infected cells

Virology (New York, N.Y.), 2006-10, Vol.354 (1), p.132-142

2006

Volltextzugriff (PDF)

Placental handling of fatty acid ethyl esters: perfusion and subcellular studies

The Journal of pharmacology and experimental therapeutics, 2004-07, Vol.310 (1), p.75

2004

Volltextzugriff (PDF)

Evaluating practice patterns for managing moderate to severe plaque psoriasis Role of the family physician

Canadian family physician, 2012-07, Vol.58 (7), p.e390-e400

2012

Volltextzugriff (PDF)

42193 Advancing Diversity in Dermatology Research: The VISIBLE Study Experience

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB13-AB13

2023

Volltextzugriff (PDF)

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (6), p.1650-1664.e8

2022

Volltextzugriff (PDF)

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2018-10, Vol.155 (4), p.1045-1058

2018

Volltextzugriff (PDF)

Social Media Influence: Performative Authenticity and the Relational Work of Audience Commodification in the Philippines

International journal of communication (Online), 2019-01, p.1939

2019

Volltextzugriff (PDF)

A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies

Journal of the American Academy of Dermatology, 2024-02, Vol.90 (2), p.349-357

2024

Volltextzugriff (PDF)

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2019-10, Vol.157 (4), p.1019-1031.e7

2019

Volltextzugriff (PDF)

Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure

British journal of dermatology (1951), 2023-07, Vol.189 (1), p.42-52

2023

Volltextzugriff (PDF)

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

Journal of the American Academy of Dermatology, 2023-08, Vol.89 (2), p.274-282

2023

Volltextzugriff (PDF)

Serum equol, bone mineral density and biomechanical bone strength differ among four mouse strains

The Journal of nutritional biochemistry, 2005-12, Vol.16 (12), p.743-749

2005

Volltextzugriff (PDF)

Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue

Journal of pediatric gastroenterology and nutrition, 2018-07, Vol.67 (1), p.45-52

2018

Volltextzugriff (PDF)

32953 Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB163-AB163

2022

Volltextzugriff (PDF)

33110 An analysis of fatigue in patients with psoriatic disease utilizing SF-36 vitality scores: Results through week 24 in phase 3 trials of guselkumab in patients with psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB137-AB137

2022

Volltextzugriff (PDF)

33055 Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB170-AB170

2022

Volltextzugriff (PDF)

33064 Correlation of fatigue severity and psoriasis severity, and the treatment effect of guselkumab: A detailed analysis of SF-36 vitality scores from the VOYAGE 2 study

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB153-AB153

2022

Volltextzugriff (PDF)

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

Drug safety, 2024-01, Vol.47 (1), p.39-57

2024

Volltextzugriff (PDF)

E088 Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials

British journal of dermatology (1951), 2023-07, Vol.189 (1), p.132-134

2023

Volltextzugriff (PDF)

S786 Psychometric Evaluation of PROMIS-Fatigue Short Form Scales in Patients With Moderately to Severely Active Crohn’s Disease

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S365-S365

2021

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(156)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Invulnerability and the intention to drink and drive: An application of the theory of planned behavior

The Severe Acute Respiratory Syndrome Coronavirus 3a Protein Up-Regulates Expression of Fibrinogen in Lung Epithelial Cells

Thermo‐Mechanically Stable, Liquid Metal Embedded Soft Materials for High‐Temperature Applications

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

The human severe acute respiratory syndrome coronavirus (SARS-CoV) 8b protein is distinct from its counterpart in animal SARS-CoV and down-regulates the expression of the envelope protein in infected cells

Placental handling of fatty acid ethyl esters: perfusion and subcellular studies

Evaluating practice patterns for managing moderate to severe plaque psoriasis Role of the family physician

42193 Advancing Diversity in Dermatology Research: The VISIBLE Study Experience

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease

Social Media Influence: Performative Authenticity and the Relational Work of Audience Commodification in the Philippines

A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease

Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

Serum equol, bone mineral density and biomechanical bone strength differ among four mouse strains

Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue

32953 Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years

33110 An analysis of fatigue in patients with psoriatic disease utilizing SF-36 vitality scores: Results through week 24 in phase 3 trials of guselkumab in patients with psoriasis and psoriatic arthritis

33055 Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2

33064 Correlation of fatigue severity and psoriasis severity, and the treatment effect of guselkumab: A detailed analysis of SF-36 vitality scores from the VOYAGE 2 study

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

E088 Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis

Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials

S786 Psychometric Evaluation of PROMIS-Fatigue Short Form Scales in Patients With Moderately to Severely Active Crohn’s Disease

Aktive Filter

Suchergebnisse filtern